GSK released data from a Phase 3 trial evaluating the co-administration of Arexvy and Shingrix vaccines in adults 50+. The ...
Global Respiratory Syncytial Virus Therapeutics Market was valued at approximately USD 5.88 billion in 2023 and is anticipated to grow with a healthy growth rate of more than 12.82% over the forecast ...
With the stock now more than cut in half from its 52-week high, the company recently laid out a plan for its business at its ...
The following is a summary of “Respiratory viral infections from 2015 to 2022 in the HIVE cohort of American households: Incidence, illness characteristics, and seasonality,” published in the August ...
Pregnant women and older people across the Bailiwick are being invited to have a respiratory virus vaccination. The Respiratory Syncytial Virus ... This is the first year of the RSV vaccine ...
Moderna is deprioritizing certain parts of its pipeline, which involves pausing work on some products and scrapping others.
Westside Current on MSN13d
Fall Respiratory Virus Vaccines: What pregnant people need to knowFall brings cooler days and more time indoors. This makes it easier for viruses like influenza (flu), COVID-19 and ...
Focuses on ten product approvals through 2027Expects to submit next-generation COVID vaccine for approval in 2024Expects to submit flu/COVID combination vaccine for approval in 2024Announces positive ...
The FDA should have more big news for Vertex only a few weeks later. It expects to announce an approval decision on ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback